The ability of OmpA to activate DCs was further supported by the observation that OmpA might function as an adjuvant in DC-based cancer immunotherapy (Kim et al., 2011, 2012), in that OmpA-pulsed DCs significantly enhanced the number of IL-2 producing CD8+ T cells and IFN-γ producing CD4+ T cells, inhibited the tumor growth, and improved the survival of tumor-bearing mice (Lee et al., 2008; Kim et al., 2012). This evidence concerns the gene CD8A and neoplasm.